Summary: Cerebral ischemia is followed by a local in flammatory response that is thought to participate in the extension of the tissue damage occurring in the postisch emic period. However, the mechanisms whereby the in flammation contributes to the progression of the damage have not been fully elucidated. In models of inflamma tion, expression of the inducible isoform of nitric oxide synthase (iN OS) is responsible for cytotoxicity through the production of large amounts of nitric oxide (NO). In this study, therefore, we sought to establish whether iNOS is expressed in the ischemic brain. Rats were killed 6 h to 7 days after occlusion of the middle cerebral artery.
In experimental animals as in humans, cerebral ischemia is followed by a marked inflammatory re action involving the ischemic brain (e.g., Pozzilli et aI., 1985; Barone et aI., 1991; Garcia et aI., 1994; Matsuo et aI., 1994) . Resident glia and vascular cells become activated, while blood-borne leuko cytes invade the area of infarction and cerebral edema develops (Garcia et aI., 1993) . There is evi dence that the inflammatory response contributes there was expression of iNOS mRNA that began at 12 h, peaked at 48 h, and returned to baseline at 7 days (n = 3/time point). iNOS mRNA expression paralleled the time course of induction of iN OS catalytic activity, deter mined by the citrulline assay (17.4 ± 4.4 pmol citrulline! f,lg protein!min at 48 h; mean ± SD; n = 5 per time point). iNOS immunoreactivity was seen in neutrophils at h after ischemia. The data provide molecular, biochemi cal, and immunocytochemical evidence of iNOS induc tion following focal cerebral ischemia. These findings, in concert with our recent demonstration that inhibition of iNOS reduces infarct volume in the same stroke model, indicate that NO production may play an important pathogenic role in the progression of the tissue damage that follows cerebral ischemia. Key Words: Cerebral isch emia-Nitric oxide-Nitric oxide synthase.
to the tissue damage because measures to attenuate the cellular infiltrate reduce the extents of cerebral ischemic damage in rat (e.g., Chen et aI., 1994; Chopp et aI., 1994; Matsuo et aI., 1994) . However, the mechanisms by which postischemic inflamma tion contributes to the progression of the ischemic damage have not been clearly elucidated. Whereas microvascular plugging by intravascular leukocytes may contribute to the injury, cytotoxic factors pro duced by inflammatory cells are also likely to play a role (see Kochanek and Hallenbeck, 1992 , for re view).
Nitric oxide (NO) is a free radical gas that acts both as a molecular messenger and as a cytotoxin (see Bredt and Snyder, 1994, for review) . During inflammation, NO is thought to mediate the cyto toxicity of activated macrophages and leukocytes (Stuehr and Nathan, 1989; Malawista et aI., 1992) .
In these cells NO is synthesized by the inducible isoform of NO synthase (iNOS), an enzyme that produces high, potentially toxic, levels of NO (see Morris and Billiar, 1994, for review) . iNOS expres sion has also been observed in astrocytes, microg lia, and vascular cells (Chao et ai., 1992; MacNaul and Hutchinson, 1993; Murphy et ai., 1993) . It is therefore conceivable that after cerebral ischemia, iNOS is expressed in the affected brain and that the large amount of NO produced by iNOS may con tribute to brain damage. In this study, therefore, we used molecular biological, neurochemical, and im munocytochemical techniques to determine wheth er iNOS induction occurs in a rat model of focal cerebral ischemia.
METHODS

Induction of focal cerebral ischemia
Focal cerebral ischemia was produced by occlusion of the middle cerebral artery (MCA). Techniques for MCA occlusion have been described previously (Zhang and Ia decola, 1992) and are briefly summarized. Male sponta neously hypertensive rats (300--400 g; Harland) were anesthetized with halothane and placed on a stereotaxic frame (Kopf). Body temperature was maintained at 37 ± O.soC by a thermostatically controlled infrared lamp. Ar terial pressure and heart rate were monitored via a fem oral arterial catheter. Plasma glucose was measured by a glucose analyzer (Beckman) . A 3-to 4-mm hole was drilled at a site superior and lateral to the left foramen ovale to expose the left MCA. The MCA was elevated and cauterized proximal to the origin of the lenticulostri ate branches (Zhang and Iadecola, 1992) . Rats in which the MCA was exposed but not occluded served as sham operated controls. Wounds were infiltrated with lidocaine and sutured. Rats were allowed to recover and returned to their cages. They were killed at different time points after MCA occlusion for determination of iN OS mRNA or enzymatic activity and for iNOS immunocytochemis try (see following).
Reverse-transcription polymerase chain reaction iN OS mRNA was detected in the ischemic brain using reverse-transcription polymerase chain reaction (RT PCR) (Kawasaki et a!., 1988) . A 4-mm-thick coronal brain slice was cut at the level of the optic chiasm, and the infarcted cortex was dissected using the corpus callosum as a ventral landmark. The homotopic region of the con tralateral cortex was also dissected. The cortex below the rhinal fissure was not sampled because at this site brain injury results also from the surgical procedures required to expose and occlude the MCA. Total RNA was ex tracted from the tissue using the method of Chomczynski and Sacchi (1987) . The integrity of RNA obtained was determined on denaturing formaldehyde gels. First strand cDNA synthesis was then carried out using 0.25, 0.5, and 1.0 fLg of total RNA, oligo-dT primer (BRL), and M-MuL V RT (New England BioLabs) according to man ufacturers' instructions. Aliquots (5 fLl each) from the RT reaction were then used for PCR amplification with primer pairs for both iN OS and a ubiquitously expressed control sequence porphobilinogen deaminase. NOS primer sequences were chosen for their ability to distinguish iNOS from the other NOS isoforms. Primer pairs used for iNOS RT-PCR were designed to flank a known intron-exon boundary of the genomic iNOS sequence. Therefore, only products corresponding to the iNOS mRNA were amplified in the RT-PCR reactions. This eliminates the concern that products might be generated from genomic DNA contaminants in the RNA samples. The iNOS primer pair used was as follows: forward 5' ACAACGTGGAGAAAACCCCAGGTG 3'; reverse: 5' ACAGCTCCGGGCATCGAAGACC 3'. The "hot start" method was employed (Stratagene) with the following cy cle parameters: 94°C, 60 s; 68°C, 60 s; 73°C, 45 s x 5 cycles then 94°C, 60 s; 62°C, 60 s; 73°C, 45 s x 35 cycles. Reaction products were then separated on a 7% acryla mide gel, ethidium stained, and photographed before re solved bands were transferred to nylon filters. Southern blot analysis of these findings using an internal iNOS cDNA was performed to confirm the identity of RT-PCR products (iNOS cDNA was provided by Drs. Q. Xie and C. Nathan). Each set of PCR reactions included control samples run without RNA/RT. Relative optical density of the bands was measured using an image analysis system (M4; Imaging Research) (Lorsbach et a!., 1993) . Multiple exposures were used to ensure that all signals were within the linear response of the film. All measurements were normalized to the relative optical density of the band of the PBD control PCR product (see Fig. 1 ).
iNOS enzymatic activity
Brain samples were collected as described in the pre vious section, frozen in liquid nitrogen within 1 min, stored at -80°C, and assayed 1-3 days after collection. iNOS catalytic activity of the postischemic cortex was determined by the citrulline assay of Bredt and Snyder modified for detection of calcium-independent activity (lade cola et a!., 1995a). As described in detail elsewhere (ladecola et a!. . Samples were applied to Dowex AG50W-X8 (Na + form) columns to remove eH]L-arginine. Columns were then washed with 2 ml of water, and eH]L-citrulline was quantified in the flow-through fraction using a liquid scin tillation spectrophotometer (Beckman LS 6000) . The level of [3H]L-citrulline was computed after subtracting the blank value, which represents nonspecific radioactiv ity in the absence of enzyme. The protein concentration of the brain samples was determined by Lowry's method using albumin as standard. The arginine-to-citrulline con version was abolished if NADPH was removed from the incubation buffer or if the NOS inhibitor nitro-L-arginine (100 fLM) was added. Procedures for validation of the iNOS assay have been described in full in another publi cation (lade cola et a!., 1995a).
Tissue culture and immunocytochemistry
The ability of iNOS antibodies to detect iNOS expres sion was tested in macrophage cultures stimulated with lipopolysaccharide (LPS). Mouse RA W264. 7 monocytes macrophages (American Type Culture Collection, Rock ville, MD, U.S.A.) were plated out at a density of _104 cells/ml into two-chamber glass slides (LabTek). One day later, the medium was replaced with growth medium con taining LPS (Escherichia coli 10 flg/ml) or vehicle (dis tilled water).Twelve hours later, cells were fixed with 4% paraformaldehyde, quenched with hydrogen peroxide, washed, and incubated with horse serum (Vector) for 3 h. Cells were then incubated overnight (4°C) with a mono clonal iNOS antibody (dilution I: 100-200; Transduction Laboratories), washed, and incubated with the secondary antibody (Vector) for 30 min. The immunocomplex was visualized using the diaminobenzidine chromogen in a peroxidase reaction (ABC complex; Vectastain Elite Kit, Vector). The specificity of the iNOS antibody was also tested by Transduction Laboratories using immunocyto chemistry and Western blotting.
For immunocytochemical studies in brain, rats (n = 3 per time point) were anesthetized (pentobarbital, 100 mg/ kg i.p.) and perfused through the heart with 4% paraform aldehyde. Brains were removed, postfixed, and embed ded in paraffin. Coronal sections (7 flm) through the in farct were cut using a microtome. Sections were deparaffinized, rehydrated, quenched with hydrogen per oxide, washed, and incubated with horse serum (Vector) for 3 h. Sections were then incubated overnight (4°C) with antibodies to iNOS (I: 100-200) or glial fibrillary acidic protein (1: 100; Boehringer). The rest of the processing was identical to that described for the RAW264.7 cells. Sections were counterstained with hematoxylin and eosin. The cell lysate of activated mouse macrophages used in control experiments was provided by Transduc tion Laboratories.
Data analysis
Enzyme activity data were expressed as means ± SD (see Fig. 2 ). Differences were statistically evaluated by the analysis of variance and Tukey's test (Systat). Prob ability values of <0.05 were considered statistically sig nificant.
RESULTS
Expression of iNOS mRNA following focal cerebral ischemia
First, we sought to determine whether iNOS mRNA is expressed in the ischemic tissue. As pre dicted from the primer pair used, peR amplification yielded a 557-bp fragment that was shown by South ern analysis to correspond to iNOS. As illustrated Top: Acrylamide gel with polymerase chain reaction prod ucts corresponding to iNOS and PBD. Bottom: Densitometric analysis of iNOS expression. Optical density (00) of the iNOS band was normalized using the corresponding PBD band. iNOS mRNA expression' starts at 12 h and is maximal at 2 days after induction of focal ischemia. Identical results were obtained in three separate sets of experiments. c, Contralat eral; s, stroke; sh, sham operated.
after MeA occlusion, iNOS mRNA returned to the basal levels seen in sham-operated rats. The time course of expression was repeated in three separate groups of rats with similar results.
iN OS enzymatic activity following focal cerebral ischemia
The results presented demonstrate that there is substantial expression of iNOS message after focal cerebral ischemia. In a parallel group of rats (n = 5 per time point), we studied whether iNOS mRNA was translated into a functional protein endowed with NOS catalytic activity. As shown in Fig. 2 , iNOS enzymatic activity developed in the area of infarction between I and 2 days after MeA occlu sion. iNOS activity started to decline at 4 days and returned to baseline by 7 days. These findings indi cate that focal ischemia leads to the development of iNOS enzymatic activity in the area of infarction.
The time course of the expression of iNOS mRNA corresponds closely to the temporal profile of iNOS enzymatic activity in the area of the infarct.
iNOS immunoreactivity following focal cerebral ischemia
We then sought to define the cell type in which iNOS expression occurs. For this purpose, a mono- clonal antibody directed against mouse macrophage iNOS was used. First, we validated the specificity of the iNOS antibody using the macrophage cell line RAW264.7. These cells express iNOS when stimu lated with endotoxins and cytokines (Lorsbach et aI., 1993) . There was no iNOS immunoreactivity in cells treated with vehicle (Fig. 3A) . However, par allel cultures treated with LPS 12 h earlier ex pressed high levels of iNOS immunoreactivity (Fig.   3B ). LPS-treated cells also developed NADPH di aphorase enzymatic activity, an index of NO . S ac tivity (Bredt and Snyder, 1994) . Thus, the INOS antibody used in these studies was able to detect iNOS expression in vitro.
We then studied whether iNOS immunoreactivity develops following focal cerebral ischemia. After MCA occlusion, iNOS immunoreactivity was ob served in polymorphonuclear cells (PMNs) invad ing the infarct border (Fig. 3D ). Positive cells were first observed 2 days after MCA occlusion and were most abundant at 4 days. Interestingly, unstained macrophages were observed near immunoreactive PMNs (Fig. 3D) . No immunoreactivity was ob served in intravascular leukocytes 36 h after MCA occlusion (Fig. 3E) . The immunoreactivity in PMNs was specific for iNOS because the stain was elimi nated by preabsorption of the primary antibodies with an excess of the antigen (Fig. 3C) . No glial fibrillary acidic protein-positive astrocytes were observed in the area of polymorphonuclear infiltra tion, but a substantial glial reaction was seen at the border of the infarct. These astrocytes, however, did not exhibit iNOS immunoreactivity. Similarly, iNOS immunoreactivity was not observed in endo thelial cells or in vascular smooth muscle cells within the area of infarction.
DISCUSSION
We have demonstrated that following focal isch emia, there is expression of iNOS mRNA and de velopment of substantial iNOS enzymatic activity in the injured brain. iNOS immunoreactivity is ex pressed in PMNs infiltrating the area of infarction.
While these results confirm our previous finding that calcium-independent NOS activity develops af ter stroke (ladecola et aI., 1995a), they demonstrate at the molecular level that there is induction of iNOS in the postischemic brain and they identify the cell type in which iNOS expression occurs.
At variance with the other NOS isoforms, iNOS produces NO continuously for the entire duration �f the life of the enzyme (Cho et aI., 1992 ; see Morns and Billiar, 1994 for review). Therefore, iNOS ex pression leads to the production of large amounts of NO. It is well established that high levels of NO are cytotoxic, an effect that is mediated through multi ple mechanisms. NO, probably via nitroysl deriva tives, depresses cellular energy production by in hibiting the glycolytic enzyme GAPDH, the Krebs cycle enzyme aconitase, and the mitochondrial en zymes complex I and II (see Stamler, 1994, for re view) . NO leads to DNA damage by deamination and inhibits ribonucleotide reductase, the rate limiting enzyme for DNA synthesis (Kwon et aI., 1991; Wink et aI., 1991) . DNA damage activates poly(ADP ribose) synthetase, a nuclear enzy�e that depletes essential substrates and may contrIb ute to neurotoxicity (see Bredt and Snyder, 1994) .
Furthermore, NO combines with superoxide to pro duce peroxynitrite, a stable oxidant that generat�s toxic free radicals (Beckman et aI., 1990) . It IS therefore conceivable that NO production by iNOS aggravates the metabolic state of the ischemic brain, thereby worsening tissue damage. Indeed, re cent studies have shown that inhibition of iNOS activity by administration of the iNOS inhibitor aminoguanidine reduces the extent of tissue damage produced by MCA occlusion in rats (Iadecola et aI., 1995b) . The reduction in infarct size is counteracted by L-but not o-arginine, suggesting that the effect of aminoguanidine is mediated through the L-arginine NO biosynthetic pathway. These observations col lectively indicate that iNOS expression plays a pathogenic role in the mechanisms of cerebral isch emic damage.
Because iNOS expression occurs >24 h after in duction of ischemia, NO production by iNOS can not account for the damage that occurs in the acute phase after stroke. Following cerebral ischemia, the majority of the tissue damage occurs within the first few hours (Dereski et aI., 1993; Garcia et aI., 1993) .
However, there is evidence from both animal and human studies that the tissue damage continues to progress for days (Heiss et aI., 1992; Dereski et aI., 1993) . After the ischemic insult, blood-borne PMNs accumulate in the affected brain; astrocytes, mi-C. lADECOLA ET AL. croglia, and vascular cells become activated; and cerebral edema develops (Pozzilli et aI., 1985; Bar one et aI., 1991; Garcia et aI., 1994) . Postischemic inflammation and cellular infiltration are thought to contribute to the progression of the tissue damage because prevention of PMN infiltration, either by induction of neutropenia prior to stroke or by using antibodies that block leukocyte adhesion to endo thelial cells, reduces the size of the infarct (Chen et aI., 1994; Chopp et aI., 1994; Matsuo, et aI., 1994) .
The mechanisms by which PMN s contribute to the damage may include microvascular plugging, pro duction of free radicals, and release of vasocontric tors (see Kochanek and Hallenbeck, 1992 ; for re view). The present study provides strong evidence that NO production by iNOS is an additional mech anism by which PMN s mediate postischemic brain damage.
In brain, many cell types have the potential of expressing iNOS during inflammatory responses (Chao et aI., 1992; MacNaul and Hutchinson, 1993; Murphy et aI., 1993) . However, after focal isch emia, iNOS induction seems to occur mainly in iNOS is an enzyme that is highly regulated at the transcriptional level. iNOS induction requires stim ulation with endotoxins and cytokines (Morris and Billiar, 1994) . These immunomodulators may inter act with specific response elements in the iNOS promoter to initiate transcription (Xie et aI., 1993) .
Furthermore, endotoxin-and cytokine-induced transcription factors such as interferon regulatory factor 1 and nuclear factor-KB are also required for iNOS induction (Kamijo et aI., 1994; Xie et aI., 1994) . Cerebral ischemia induces the expression of tumor necrosis factor-a and interleukins (Liu et aI., 1993 (Liu et aI., , 1994 Buttini et aI., 1994) . Inhibition of iNOS expression or activity may rep resent a useful strategy for mitigating the conse quences of cerebral ischemia in stroke patients.
